FOR IMMEDIATE RELEASE
What: The American Society of Clinical Oncology Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
Where: McCormick Place in Chicago
When: June 1-5, 2018
Session presentations (all times Central):
Saturday, June 2 at 5:20 p.m/Hall B1
ALT-803, an IL-15 superagonist, in combination with nivolumab in metastatic non-small cell lung cancer: Ongoing experience and biomarker development from a non-randomized, open-label, phase Ib/II trial.
John Wrangle, M.D., MPH
PD-1/PD-L1 blockade fails to yield a response in about 80% of unselected non-small cell lung cancer (NSCLC) patients and acquired resistance will lead to treatment failure in most responders. Cytokine therapy with IL-2/IL-15Rbg agonists has demonstrated durable responses in select solid tumors, though the response rates are low. In this phase Ib/II trial NSCLC patients received anti-PD1 immunotherapy in combination with ALT-803, an IL-15 super-agonist. There is encouraging anti-tumor activity with the combination of nivolumab with ALT-803. Phase II study of the combination is ongoing.
Sunday, June 3 at 8:20 a.m./Room S404
Cardiorespiratory fitness and incident lung and colon cancer: FIT-Cancer Cohort.
Catherine Handy, M.D., MPH
Cardiorespiratory fitness (CRF), an objective measure of exercise tolerance, is a strong predictor of cardiovascular disease and mortality yet its relationship with cancer incidence is unclear. In the largest study of its kind, CRF measured during exercise testing is a strong predictor of future lung and colon cancer risk. The study provides another important reason for optimizing CRF.
Monday, June 4 at 9:45 a.m./Arie Crown Theater
Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358.
Suzanne Topalian, M.D., associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy
MCC is a rare, aggressive skin cancer commonly associated with the oncogenic Merkel cell polyomavirus (MCPyV). The PD-1/PD-L1 immunosuppressive pathway is often upregulated in MCC, and advanced metastatic MCC is responsive to PD-1 blockade. This study is the first trial of anti–PD-1 in the neoadjuvant setting for resectable MCC. Nivo administered for 4 weeks before surgery in MCC was safe and induced substantial radiologic and pathologic tumor regressions in 45 percent and 65 percent of patients, respectively. In some patients, this obviated the need for more extensive surgery.
Monday, June 4 at 10 a.m./Arie Crown Theater
Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy.
Paul Nghiem, M.D., Ph.D (University of Washington), Suzanne Topalian, M.D., associate director of the Bloomberg~Kimmel Institute for Cancer Immunotherapy
Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus (MCPyV). Clinical trials of PD-1-axis blocking agents in aMCC have demonstrated increased progression free survival (PFS) compared to historical data from patients (pts) receiving chemotherapy, but data on response durability and OS are limited. Here we report outcomes from the expanded phase 2 Cancer Immunotherapy Trials Network-09 trial of pembrolizumab (PEM, anti-PD-1) in the first-line setting (NCT02267603).
Poster abstracts:
Saturday, June 2/Hall A
8:00 AM - 11:30 AM
Poster Board: #3 • Abstract 511
Roisin M. Connolly, M.B.B.Ch., M.D.
TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer.
Poster Board: #355 • Abstract 4529
Jean H. Hoffman-Censits, M.D.
Atezolizumab (atezo) in special populations: Analyses from an expanded access program (EAP) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).
1:15 PM - 4:45 PM
Poster Board: #364 • Abstract 6538
Jarushka Naidoo, M.B.B.Ch.
A multidisciplinary toxicity team for cancer immunotherapy-related adverse events.
Poster Board: #289 • Abstract 5062
Catherine Handy, M.D., MPH
Prevalence of homologous recombination deficiency (HRD) mutations in localized prostate cancer according to Gleason grade: Implications for neoadjuvant clinical trial design
Poster Board: #317b • Abstract TPS5095
Mark Christopher Markowski, M.D., Ph.D.
Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).
Poster Board: #319b • Abstract TPS5099
Eugene Shenderov, M.D., D.Phil.
Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.
Sunday, June 3
8:00 AM - 11:30 AM
Poster Board: #7 • Abstract 3514
Dung T. Le, M.D.
KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer.
Poster Board: #50 • Abstract 3557
Nilofer Saba Azad, M.D.
ENCORE 601: A phase 2 study of entinostat in combination with pembrolizumab in patients with microsatellite stable metastatic colorectal cancer.
Poster Board: #220 • Abstract 4031
Ronan Joseph Kelly, M.B.A., M.B.B.Ch., M.D.
Safety and efficacy of durvalumab in combination with tremelimumab, durvalumab monotherapy, and tremelimumab monotherapy in patients with advanced gastric cancer.
Poster Board: #258 • Abstract 4069
Alessandro Leal
Circulating tumor DNA dynamics in resectable gastric cancer.
Poster Board: #324b • Abstract TPS4140
Ronan Joseph Kelly, M.B.A., M.B.B.Ch., M.D.
Induction nivolumab or nivolumab/ipilimumab prior to concurrent chemoradiation plus nivolumab in patients with operable stage II/III esophageal/gastroesophageal junction cancer.
Poster Board: #330a • Abstract TPS4151
Marina Baretti
Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.
Poster Board: #145 • Abstract 8539
Chen Hu, M.S., Ph.D.
Progression-free survival (PFS) and cardiac-toxicity-adjusted-PFS (CTA-PFS) as predictors of overall survival (OS) in locally advanced non-small cell lung cancers (LA-NSCLC) treated with concurrent chemoradiation (CCRT): A secondary analysis of NRG Oncology RTOG 0617.
Poster Board: #433b • Abstract TPS9117
Benjamin Philip Levy, M.D.
Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.
Monday, June 4
Poster Board: #77 • Abstract 7017
Mark J. Levis, M.D., Ph.D.
Post hoc exploratory analysis of two phase 2 trials of quizartinib monotherapy in patients (pts) with FLT3-ITD–mutated (mu) relapsed/refractory (R/R) AML with or without prior 1st-generation FLT3 tyrosine kinase inhibitors (TKI) treatment.
Poster Board: #370 • Abstract 2544
Channing Judith Paller, M.D.
FACTS: Factors affecting combination trial success
Poster Board: #134a • Abstract TPS7075
Mark J. Levis, M.D., Ph.D.
A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML.
RSS